Both clinical and experimental evidence indicate that T lymphocytes can mediate antileukemic effects in acute myelogenous leukemia (AML). These antileukemic effects can be either nonspecific cytotoxicity (killer cell activity) or reactivity against leukemia-specific antigenic peptides presented by self-HLA molecules. The antigen-specific T cell activation requires recognition of specific peptides together with costimulatory signalling. For most patients the AML blasts express both HLA class I and class II molecules for antigenic presentation, but patients are heterogeneous with regard to: (1) expression of costimulatory binding molecules; (2) expression of receptors/counterreceptors involved in induction of apoptosis; (3) constitutive release of immunomodulatory soluble mediators. This heterogeneity suggests that the ability of AML blasts to initiate an antileukemic T cell response will differ between individual patients. Thus, clinical approaches for immunotherapy in AML have to overcome three major problems. First, the therapy should reduce the patient heterogeneity so that therapeutic effects become more predictable; or alternatively one should define patient subsets which are likely to benefit from immunotherapy. Second, immunotherapy should enhance antileukemic T cell reactivity or blast susceptibility to immune attacks. Third, the therapeutic procedures must be safe and suitable for routine use. All three problems probably have to be solved before immunotherapy can become a routine treatment.
Introduction
T lymphocytes recognize antigenic peptides bound to HLA molecules which are expressed on autologous antigenpresenting cells, and this phenomenon is called HLA restriction. 1 Thus, the T cell repertoire of an individual encompasses cells which can recognize antigens in the context of this limited number of HLA molecules (referred to as self-HLA molecules). One would also expect HLA-restricted presentation to be necessary for the recognition of leukemia-specific antigenic peptides. Animal studies have shown that this presentation of tumor-specific antigens can be performed either directly by the malignant cells themselves, or indirectly by normal professional antigen-presenting cells (eg dendritic cells) infiltrating the malignant cell population. [2] [3] [4] Both these presentation pathways may also be operative during T cell responses against acute myelogenous leukemia (AML) blasts. However, antigenic recognition alone is not sufficient to initiate a T cell immune response, adequate costimulatory signals (eg binding of costimulatory molecules to T cell ligands, release of costimulatory cytokines) are, in addition, required before recognition can result in T cell activation. 5 The classical HLA molecules are grouped into HLA class I (HLA-A, -B, -C molecules) and class II molecules (HLA-DP, -DQ, -DR). 1 HLA class I molecules are expressed on all nucleated cells and present antigenic peptides to CD8
+ T lymphocytes, whereas HLA class II molecules are expressed particularly on immunocompetent cells (including the professional antigen-presenting cells) and present peptides to CD4
+ T lymphocytes (for review see Refs 1, 6) . The CD4 and CD8 molecules are also important for antigen-specific T cell activation by mediating additional binding to nonpolymorphic determinants on the HLA molecules.
Antigenic peptides bound to self-HLA molecules are recognized by the T lymphocyte antigen receptor (TCR). The HLAantigen complex is presented to the T cells in the cell membrane of antigen-presenting cells (also termed accessory cells). The TCR consists of two polypeptide chains (␣␤ or ␥␦ receptors) which bind to the HLA-peptide complex. The CD3 molecular complexes (␦, ␥, ⑀, and chains) are closely linked to the antigen receptor, and T cell activation can even be initiated by anti-CD3 specific monoclonal antibodies. The T lymphocytes recognize peptides bound to self-HLA molecules, whereas peptides bound to foreign HLA-molecules (ie HLA molecules expressed only on allogeneic cells) are generally not recognized. The CD4 and CD8 molecules will mediate additional binding to nonpolymorphic determinants on the HLA class II and class I molecules, respectively. Adhesion between T cells and accessory cells is also mediated by binding of LFA-3 (CD58) to its T cell ligand CD2. In addition, LFA-1 (CD11a/18) and its ligand ICAM-1 (CD54) are both expressed on T lymphocytes as well as on accessory antigen-presenting cells, and in addition, T lymphocytes express CD43 which is a second ligand for ICAM-1. The accessory cell molecules B7.1 and B7.2 bind to the T lymphocyte molecules CD28 and CTLA-4, and thereby mediate costimulatory signals during T cell activation (see Refs 1, [6] [7] [8] [9] . Thus, antigen-specific T cell activation depends both on TCR recognition of the antigen/HLA complex, and on costimulatory signals mediated by additional binding between T cells and their accessory antigen-presenting cells.
Although the normal T cell repertoire may encompass leukemia-specific reactivity, 7 malignant cells can escape from host antitumor immunity by several mechanisms (reviewed in Ref. 8 ). The present article reviews both molecular mechanisms which may be involved in immune recognition of AML blasts, and possible mechanisms by which AML blasts can escape host immunity.
Clinical evidence for antileukemic T lymphocyte reactivity
The clinical evidence for antileukemic immune reactivity has mainly come from studies of allogeneic bone marrow trans-plant (BMT) recipients. These studies have been reviewed previously, 9 and in the present article we will only discuss the results from certain selected studies (Table 1) .
The antileukemic effects after allo-BMT are mediated both by graft-versus-host disease (GVHD)/reactivity (allorecognition) and the graft-versus-leukemia (GVL) effects (leukemia-specific recognition, see Ref. 9) . The importance of allorecognition as an antileukemic effector mechanism is clearly demonstrated by the reduced risk of GVHD (and transplant-related mortality) together with an increased risk of posttransplant leukemia relapse in identical twin BMT compared with HLA-identical sibling transplants. 10 Because a second allotransplant is usually associated with very poor prognosis, 11 immunotherapy with donor leukocyte infusions has been used in the treatment of leukemia relapse after allo-BMT. In chronic myeloid leukemia (CML) approximately 70% of the patients with cytogenetic and chronic phase relapse enter complete hematological remission after leukocyte transfusions from HLA-identical sibling donors, 12, 13 and the probability of remaining in complete remission at 3 years seems to be 80-90% for these patients. 13 Although the anti-CML effect seems to correlate with clinical signs of GVHD, 12 complete remission can also be achieved when transfusing low T cell numbers with a minimal risk of clinical GVHD.
14 The anti-CML effect may be further enhanced by combining leukocyte transfusion with interleukin 2 (IL2) therapy. 15 Leukocyte transfusions seem less effective in the treatment of AML relapse, and only 15-30% of these patients enter a complete remission. 12, 13, 16 The remission in AML patients is usually of short duration (12-18 months) compared with CML, but long-term survival has been observed in a few patients. 12, 13 Although a stronger GVHD-associated antileukemic effect would be expected when using leukocyte infusions from partially HLA-mismatched related donors, long-lasting AML control is usually not observed even in these patients despite their high frequency of serious GVHD.
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Table 1
Clinical and experimental evidence for antileukemic T cell activity in humans: a summary of available evidence
Clinical studies in allogeneic bone marrow transplant recipients Increased risk of leukemia relapse, decreased risk of GVHD and transplant-related mortality in identical twin transplants 10 Complete remission has been observed after treatment of post-transplant AML relapse with donor leukocyte transfusions [12] [13] [14] [15] [16] [17] The frequencies of host reactive helper and cytotoxic T lymphocytes in stem cell donors correlate with the risk of GVHD 23, 24 Cytotoxic T cells recognizing minor histocompatibility antigens can inhibit AML blast proliferation 27 AML blasts expression of membrane molecules necessary for antigen-specific T cell activation AML blasts express HLA class I and class II molecules which are capable of presenting processed antigenic peptides [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] AML blasts express molecules mediating costimulatory signals (LFA-3, ICAM-1, B7.1, B7.2) effects during antigen-specific T cell activation 29, 71, [99] [100] [101] [102] [103] [104] Normal T cell recognition of leukemia-specific antigenic peptides
The normal T cell repertoire may encompass cells capable of recognizing synthetic leukemia-specific hybride peptides (pml/RAR␣ in AML-M3 and the BCR/ABL in CML blast phase cells) [47] [48] [49] [50] [51] [52] [53] BCR/ABL peptide specific clones can recognize CML blast phase cells 48, 53 AML blasts as accessory cells during T cell activation AML blasts can process and present HLA-bound peptides 56 AML blasts can function as accessory cells during T cell activation in response to anti-CD3 stimulation, alloantigen recognition and mitogenic T cell activation [60] [61] [62] 177 It is not known why donor leukocyte infusions are less effective in AML than in chronic phase CML. Possible explanations could be (1) a decreased sensitivity of AML blasts to antileukemic effector mechanisms or (2) a heterogeneity of leukemia-specific antigens between AML patients (different cytogenetic abnormalities) which makes immunotherapy less effective in AML than in CML where the majority of patients express the same T cell recognized, BCR-ABL encoded hybrid molecules (see below).
Several observations indicate that AML relapse may be associated with decreased immune recognition of the leukemia blasts. First, relapse AML blasts may show lower expression of the T cell allostimulatory HLA-DR molecules and/or costimulatory molecules, 18 and as would be expected, the relapse AML blasts then show a reduced capability to induce T cell alloresponses compared with the primary leukemia cells. 19 These results may further suggest that the ability to present other antigens (eg leukemia-specific peptides), is decreased in relapse AML blasts. However, this decreased capacity to induce antigen-specific alloreactivity seems to be at least partly counteracted by an increased susceptibility to HLA-nonrestricted lymphokine activated killer (LAK) lysis for relapse AML cells. 19 Second, the HL-60 myeloid leukemia cell line which does not express HLA class II molecules, is also an ineffective stimulator for alloreactive T lymphocytes. 20 However, treatment with all-trans retinoic acid induces HLA class II expression, and the cells become capable of stimulating alloreactive CD4
+ and CD8 + T cells. 20 The importance of HLA class II expression for allorecognition was also demonstrated by Delain et al, 21 who described an extremely low frequency of donor cytotoxic T lymphocyte precursors reactive against HLA-DR negative host/recipient leukemia blasts, whereas higher frequencies were detected when leukemic stimulator cells expressed HLA-DR. However, confirmatory studies are needed before one can judge whether immune escape due to decreased immunostimulatory capacity pro-vides an explanation for the reduced effect of donor leukocyte transfusions in post-transplant AML relapse.
Studies of GVHD have demonstrated that several subsets of immunocompetent cells can mediate antileukemic activity after allo-BMT. 16, 22 First, a high frequency of alloreactive/ antirecipient IL2-producing (helper) T lymphocyte precursors in the blood of bone marrow donors is associated with an increased risk of serious GVHD. 23 Second, donor-derived cytotoxic T lymphocytes recognizing host minor histocompatibility antigens are also involved in the pathogenesis of GVHD. 22 Antileukemic immune reactivity after autologous stem cell transplantation is less well characterized. IL2 therapy after auto-BMT can induce effects which both histologically and clinically mimic acute GVHD, 28 but it is not known whether this reaction has a similar antileukemic effect as GVHD.
AML blasts as antigen-presenting cells
Expression of HLA molecules by AML blasts
HLA class I and class II molecules are expressed on the AML blasts for most patients. Hirano et al 29 investigated AML blasts derived from 92 patients, and all cases were positive for HLA class I and with a strong expression on Ͼ90% of the blasts for 89 out of the 92 patients. For most patients the AML blasts express HLA-DR molecules also, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] but the expression of other class II molecules is less well characterized. HLA class II expression is independent of FAB classification, the only exception being the AML-M3 subtype where significantly lower levels of class II expression are detected. [30] [31] [32] Thus, for the large majority of patients AML blasts express the self-HLA molecules needed for presentation of antigenic peptides to T lymphocytes. However, several studies have demonstrated that this HLA class II expression can vary between different AML blast subsets even within the same patient. Such intraclonal heterogeneity can be detected in approximately 30% of AML patients. The more differentiated large leukemia cells express HLA class II molecules at a higher level than the less differentiated smaller cells, 34 but HLA class II expression can be detected even on the most immature clonogenic colonyforming AML cells. 35 Although two studies have addressed the question whether this intra-and interpatient variation in HLA class II expression is important for the outcome after chemotherapy, it is still too early to make an answer to this question.
30,39
Leukemia-specific antigenic peptides and their binding to HLA molecules
For many patients the AML blasts show chromosomal abnormalities (eg translocations, mutations, inversions, see Ref. 41 ). The chromosomal translocations often involve components of the transcription machinery, and the expressed fusion proteins may then result in fundamental alterations in the regulation of cell proliferation or apoptosis. [42] [43] [44] [45] [46] At the same time expression of fused or mutated proteins forms a molecular basis for the expression of leukemia-specific peptide sequences. However, T cell reactivity against such leukemiaspecific hybrid peptides has been demonstrated only for a limited number of abnormalities, including the pml/RAR␣ fusion protein in the 15, 17 translocation, 47 and the BCR-ABL fusion protein of the 9, 22 translocation. [48] [49] [50] [51] [52] [53] T cell responses against the BCR-ABL fusion protein have been most extensively investigated. Peptide-recognizing T lymphocytes were then detected both among the CD4 + and CD8 + repertoire, and both subsets could mediate peptide-specific cytotoxicity. [47] [48] [49] [50] [51] [52] [53] The peptide-recognizing T cells were detected only at a low frequency in the repertoire of healthy individuals and were not detected in leukemia patients. 47, 50 Although only two leukemia-specific antigens have been investigated and these studies include a relatively small number of patients, 47, 50 these results indicate that leukemia-specific T cells are less frequent in patients than in healthy individuals. This decreased frequency in patients can be explained by different mechanisms: (1) AML blasts do not express B7 molecules and may thereby induce anergy in autologous leukemia-specific T cells; or (2) AML blasts may induce Fas-mediated apoptosis in specific T cells (for a detailed discussion see below). If such differences exist between healthy individuals and patients, immunotherapy involving autologous T cells would be expected to be less effective than transplantation/infusion of allogeneic leukocytes in combination with normal antigen-presenting cells.
The capability of self-HLA molecules to bind and thereby present leukemia-specific antigenic peptides would be expected to depend on immunogenetic factors. This is further supported by the observation that synthetic BCR/ABL peptides show selective binding to certain HLA class I and class II molecules, whereas other molecules cannot bind the peptides. 50, 54, 55 Due to immunogenetic differences one would therefore expect HLA class I (CD8 + cells) and class II (CD4 + cells) T cell responses against defined antigenic peptides to occur only in certain subsets of patients.
Peptide processing by AML blasts
The existence of hybrid molecules with leukemia-specific peptide sequences is probably not sufficient for initiation of an antileukemic T cell response, because T cell activation will in addition require adequate antigen processing to short peptides which can bind to self-HLA molecules. The ability of leukemia blasts to process peptide antigens has been investigated for the myeloid leukemic cell line KG-1. 56 In the absence of antigenic peptides the HLA molecules will bind peptides derived from self proteins, [1] [2] [3] [4] [5] [6] and the ability of the KG-1 cells to process peptides was therefore characterized by sequencing self-peptides bound to HLA-DR molecules. All the sequenced peptides corresponded to intracellular proteins, whereas sequences corresponding to transmembrane and exogenous proteins were not detected. 56 This absence of the conventional self-peptide repertoire suggests that the antigenprocessing pathways of these leukemia cells are different from those characterized in professional antigen-presenting cells. However, these results should be interpreted with caution because only a limited number of predominant self-peptides derived from a single cell line has been investigated. In fact, the observation that T cell clones primed against synthetic BCR-ABL hybrid peptides can recognize native CML blast phase cells demonstrates that the HLA class II antigen-processing pathways in undifferentiated leukemia cells are suf-ficient for the processing and presentation of at least certain leukemia-specific antigenic peptides. 48, 53 Mutations form a molecular basis for the expression of leukemia-specific antigenic epitopes; but mutations may in addition alter the proteosomal cleavage/processing of protein antigens. A mutation close to a normal cleavage point in the polypeptide chain may then result in the production of peptides with an altered length and thereby an altered binding to and presentation by the HLA molecules. 57 The altered cleavage may then cause a lack of expression of naturally recognized T cell epitopes in the flanking region of the mutation, and malignant cells may thereby escape from immune recognition. 57 This escape mechanism may become important for the recognition of mutated minor transplantation antigens after allo-BMT.
Partial activation of T lymphocytes by modified antigenic peptides
Activated T cells secrete several cytokines which serve as AML blast growth factors (eg GM-CSF, IL3). This is observed for most CD4
+ and CD8 + clonogenic T cells derived from both normal individuals, allogeneic bone marrow transplant recipients as well as AML patients with chemotherapy-induced leukopenia. [58] [59] [60] [61] [62] Although quantitative differences may exist between various T cell subsets or individual T cell clones, most clones show a qualitatively similar broad cytokine response. An antigen-induced T cell cytokine response may therefore enhance AML blast proliferation. This hypothesis is also supported by in vitro studies. First, when testing the effects on AML blast proliferation of supernatants derived from a panel of activated T cell clones, addition of supernatants during in vitro blast culture caused either enhanced or inhibited blast proliferation depending on individual differences between AML patients. 60 Second, Yasukawa et al 51 observed that CD4 + cytotoxic, BCR-ABL-specific T cell clones could lyse normal peptide-pulsed target cells, whereas coculture of clones and CML cells caused enhanced leukemia cell proliferation. A possible explanation for this enhancement is antigen-stimulated release of hematopoietic growth factors by the T cells during coculture with BCR-ABL expressing CML cells. Taken together these studies indicate that (1) whether a T cell cytokine response will modulate AML blast proliferation depends on differences in cytokine responsiveness between patients; and (2) for certain patients the enhancing effects of a cytokine response may dominate over T cell cytotoxicity against the leukemia cells.
T cell recognition of a native antigenic peptide usually results in activation followed by proliferation and enhancement of several T cell effector functions (eg cytotoxicity, cytokine secretion, B cell help). However, in vitro studies have demonstrated that the effector functions of both human and murine antigen-specific T cells can be modulated by altering the amino acid sequence (but not the peptide length) of the recognized antigenic peptide. [63] [64] [65] [66] [67] [68] [69] Restimulation of antigenspecific T cells with synthetic peptides with single amino acid substitutions may then result in enhancement of only certain T cell functions, whereas other effector functions are not stimulated/enhanced by the substituted peptides. This phenomenon has been called partial activation and has been described both for CD4 + and CD8 + T cells and for cytotoxic as well as for helper T cells. By using single amino acid substitutions T cell proliferative responses can be separated from cytokine secretion and B cell help. Altered peptide ligands can also be used to separate cytotoxic activity from proliferation and cytokine production, because fewer amino acids seem to be critical as contact residues for cytolysis than for other effector functions. 67 Such modulation of effector functions may also become useful in immunotherapy for AML. In vivo or in vitro exposure of leukemia-specific T cells to modulated synthetic peptides may then be used to separate cytotoxicity from cytokine secretion, and exposure to synthetic peptides may thereby be used to enhance cytotoxicity against leukemia cells without concomitant release of AML blast stimulating growth factors by the T cells.
Recent studies have demonstrated that macrophages exposed to GM-CSF can mediate antileukemic effects. 70 A T cell cytokine response including GM-CSF release may thereby indirectly enhance antileukemic effects mediated by other cells in the common in vivo AML blast/T cell microenvironment. Thus, before altered peptides are tried as modulators of cytokine responses in AML, the effects of partial activation of leukemia-specific T cells need to be characterized in detail in experimental models not only taking into account the AML/T cell interactions.
Expression of costimulatory molecules by human AML blasts
Recognition of the antigenic peptide-HLA complex is essential for antigen-specific T cell activation, but additional costimulatory signals are also required to complete the activation process. This costimulation can be mediated by several accessory cell molecules and their counter-receptors expressed in the T cell membrane (Table 2) . Several soluble mediators can modulate the AML blast expression of these molecules. The mediators either enhance the expression or they have divergent effects, whereas no mediator with only inhibitory effects has been described. Whether T cell recognition of antigenic epitopes on AML blasts will result in an immune response, may thus depend on the expression of costimulatory membrane molecules by the accessory leukemia cells. Antigenic recognition in the absence of adequate costimulation may result in T cell anergy.
5,8
Expression of LFA-3 (CD58) by AML blasts
LFA-3 is the ligand for the CD2 molecule which is expressed on T lymphocytes and NK cells. High AML blast expression of LFA-3 is observed for most patients. Reuss-Borst et al 71 described that more than 70% of the leukemia blasts stained positive for LFA-3 in 111 out of 113 AML patients investigated.
Expression of B7.1 (CD80) and B7.2 (CD86) by AML blasts
The B7 molecular family consists of the two members B7.1 (CD80) and B7.2 (CD86), but there is also experimental evidence for a third member of the family. 5 The T cell molecule CD28 is a common counter-receptor for B7.1 and B7.2.
72-79
The B7 family seems unique among the T cell costimulatory molecules, since ligation by either B7.1 or B7.2 of their counter-receptor CD28 is both sufficient and necessary to prevent the induction of T cell anergy.
72,73
The CD28 molecule is constitutively expressed on 95% of 
resting CD4 + T cells and on 50% of resting CD8
+ peripheral blood T lymphocytes, and its expression increases following activation. 78 Both B7.1 and B7.2 are members of the immunoglobulin supergene family, they have partial amino acid homology, [79] [80] [81] [82] [83] and their expression is restricted to cells which can function as antigen-presenting cells, eg dendritic cells, monocytes and activated B cells. 81, 84 The second T cell receptor for B7 molecules is the cytotoxic T lymphocyte antigen 4 (CTLA-4) 85 which is only expressed on activated T cells 83, 84 and seems to deliver an inhibitory signal. 86, 87 T cell recognition of the peptide-HLA complex without CD28 costimulation results in T cell anergy on secondary challenge. The anergy cannot be reversed by later CD28 costimulation, 5, 72, 73 but it can be prevented by addition of exogenous IL2, IL4 or IL7 during otherwise anergizing conditions (for detailed information see Refs 5, 75, 88, 89) . The receptors for these three cytokines share a common gamma chain, 90, 91 and the critical signal to prevent anergy may therefore not be mediated directly through the CD28 pathway, but rather depend on signalling through this common interleukin receptor component. 5 Consistent with these observations it has been hypothized that the inhibitory signal of B7/CTLA-4 represents a distinct signal pathway capable of clonally deleting previously activated T cells if the TCR signalling is not accompanied by significant IL2 accumulation. 5, 86 In a recent study, AML blast expression of B7.1 and B7.2 was investigated for 54 patients, and blast populations containing more than 20% of positive cells were then defined as positive cases. 29 Only one of the 54 patients had B7.1 positive blasts, whereas B7.2 positive blasts were detected for 15 patients. The effects of soluble mediators on the B7 expression has been investigated both for AML cell lines and native AML blasts (Table 2) . 29, 92, 93 First, in a study including 13 cell lines which were heterogeneous with regard to expression of B7.1 and B7.2, tissue plasminogen activator and retinoic acid had minor and divergent effects on B.7 expression only in a minority of cell lines, IFN␣ caused slightly increased expression in a minority of lines, whereas the T cell cytokine IFN␥ exhibited potent inducibility of both B7.1 and B7.2 in a majority of the cell lines. 29 Second, a dendritic cell phenotype with increased B7 expression can be induced after in vitro exposure of native AML blasts to several cytokine combinations, including the T cell cytokines IL4+GM-CSF (+ eventually IL13), 92, 93 GMCSF+stem cell factor (SCF)+Flt-3 ligand (Flt-3L), and TNF␣+GM-CSF+SCF. 94, 95 Such phenotypically altered AML cells seem to be more efficient than native blasts as accessory cells during T cell activation. 93 Thus, AML patients are heterogeneous with regard to constitutive B7 expression and to the effects of single soluble mediators on B7 expression, but this heterogeneity seems to be reduced by exposure of the blasts to cytokine combinations. However, due to this heterogeneity the use of native or in vitro modulated AML blast stimulator cells to enrich leukemia-reactive T cell populations should probably be combined with cytokine therapy (eg IL2 therapy, see above) to reduce the risk of inducing T cell anergy in patients with absent or suboptimal B7 expression.
Animal studies indicate that immune responses against malignant cells can be enhanced by presentation of tumor antigens by tumor-infiltrating normal dendritic cells, ie specialized antigen-presenting cells with high B7.1 and B7.2 expression. 2, 8, 96 However, evidence from both animal models and studies in human tumors suggests that decreased B.7 expression by normal tumor-infiltrating dendritic cells may be a mechanism for immune escape in malignant disorders. 97, 98 It is not known whether modulation of normal dendritic cells can be used to avoid immune escape or enhance presentation of leukemia-specific antigens in AML.
Only limited data are available on B7 expression as a prognostic factor in AML. In a recent study, B7.2 positive AML was associated with a poor prognosis. 99 These results need further confirmation, but they may indicate that B7.2 expression is associated with other functional characteristics which are prognostically dominant to an increased immunostimulatory capacity.
Expression of ICAM-1 (CD54) by AML blasts
ICAM-1 is a T cell binding molecule which is expressed on AML blasts only in a minority of patients, 71 ,100-104 but its Inhibition of T cell activation demonstrated by in vitro models 137, 138 Cytokine antagonists IL1RA 132 Blocking of IL1 receptors and thereby inhibition of IL1 effects during T cell activation 132, 133 sIL2R 163 Binding of IL2 and thereby inhibition of autocrine proliferation of activated T cells 8, 152 Soluble adhesion molecules sICAM-1 165 Inhibition of binding and thereby costimulation between T cells and accessory antigenpresenting cells?
expression can be enhanced or induced by in vitro culture in medium alone and especially by exposure to IFN␥, TNF␣ or GM-CSF (Table 3) . 100, 103, 104 All these cytokines are secreted by activated CD4
+ and CD8 + T cells, [58] [59] [60] [61] [62] and a T cell cytokine response may thus enhance ICAM-1 expression (as well as B7
Figure 1
AML blasts were cultured in vitro for 48 h at a concentration of 1 × 10 6 cells/ml before concentrations of various soluble mediators were determined in the supernatants. [129] [130] [131] [132] 165 The figure presents the results for those patients who showed detectable (b) and undetectable (᭺) levels of IL1␣, IL1␤, IL1RA, IL6, TNF␣, GM-CSF, soluble IL2 receptor ␣ chain (sIL2R␣) and slCAM-1. It can be seen that the cytokine or cytokine antagonist levels showed a wide variation, whereas the levels of soluble IL2 receptors and sICAM showed a relatively narrow variation range. The percentage of ICAM-1-positive AML blasts varied between 0 and 45%, and membrane ICAM-1 expression showed no correlation to sICAM-1 release. This appearent contrast between ICAM expression and release can probably be explained by induction of high 104CAM-1 expression in most patients during in vitro culture. 100, 104 expression, see above) and thereby amplify leukemia-specific T cell reactivity. The GM-CSF induced enhancement of ICAM-1 expression will also increase AML blast susceptibility to HLA-nonrestricted lysis by cells with LAK activity, eg T cells and activated NK cells. 105 A soluble form of FasL (sFasL) has also been detected, although this soluble form may have less biological activity than the membranebound molecules. 105 When both malignant cells and T lymphocytes express Fas and FasL, bidirectional killing of both cell types may occur. [115] [116] [117] Induction of T cell apoptosis by soluble FasL may thereby contribute to T cell death. The overall in vitro studies thus indicate that Fas/FasL interactions are involved in malignant cell apoptosis, tissue damage and/or immune escape by the malignant cells. 105, 115 However, when using an in vitro cytotoxicity assay it should be emphasized that there is a fundamental difference between this standard assay with an excess of effector to target cells, and the in vivo situation where the effector to target ratio is almost always in favor of the malignant cells. 105, 118 This is particularly true in untreated AML with at least 30% leukemia blasts in the bone marrow, 119 and Fas/FasL-induced bidirectional killing may then become an immune escape mechanism for the excess AML blasts.
Fas expression in AML blasts varies between patients as well as within the same blast population, [120] [121] [122] [123] [124] [125] [126] [127] and this variability may be an explanation for the relatively large range of reported frequencies in AML patients with Fas + blasts. In one study only a minority (30%) of patients was judged to have Fas + blasts, 120 whereas in another study 80% of patients were positive. 121 The intrapatient variation seems to be caused by high Fas expression on CD34 + CD38 high AML cells, whereas lower levels are often observed in CD34 + CD38 low and CD34 − subsets. 121 Although native AML blasts are heterogeneous with regard to Fas expression, both in vitro culture in medium alone and blast exposure to IFN␥ and TNF␣ will induce or increase Fas expression for most patients. 104 In vitro studies suggest that Fas/FasL interactions may be involved in non-HLA-restricted cytotoxicity against AML blasts, including LAK cell lysis mediated by activated CD56 + NK and CD3 + T cells. 122, 123 First, FasL can be detected on activated T lymphocytes, 105, 115, 127 and Fas-blocking antibodies seem to inhibit the T cell-induced apoptosis of AML cells. 123, 124, 126 Second, IL3 and GM-CSF can increase the susceptibility of myeloid leukemia cells to both LAK cell lysis and Fas-induced apoptosis. 123, 125, 127 Taken together, these observations are consistent with the hypothesis that Fas/FasL interactions are important for non-HLA-restricted LAK cell cytotoxicity against myeloid leukemia cells.
Activated CD4 + and CD8 + T lymphocytes secrete GM-CSF, IL3, IFN␥ and TNF␣ [58] [59] [60] [61] which all interfere with the Fas/FasL system. 104, 121, 127 A T cell cytokine response may thereby increase AML blast susceptibility to Fas/FasL-induced apoptosis both by increasing the Fas expression of AML blasts (IFN␥, TNF␣) [121] [122] [123] and by an additional mechanism related to cytokine-dependent cell cycle progression and not involving Fas expression (IL3, GM-CSF). 127 However, AML blasts also express FasL, 128 and AML blast T cell interactions via the Fas/FasL system may thereby induce bidirectional killing resulting in T cell apoptosis and AML blast immune escape. 107, 115, 117 A recent study described a significant correlation between Fas expression by AML blasts and the response to induction chemotherapy. 121 However, further studies are definitely needed before a conclusion can be reached about Fas expression as a possible prognostic factor in AML.
AML blast release of cytokines with an enhancing effect on T lymphocyte responses
For most patients the AML blasts show constitutive secretion of several cytokines (including IL1␣, IL1␤, IL6 and TNF␣; see and the cytokine antagonist IL1 receptor antagonist (IL1RA). 132 All these cytokines can enhance T cell responses (Table 3 ; Refs 133-135). Secretion of these cytokines as well as IL1RA shows a wide variation between individual patients (Figure 1) . It is not known whether this variation is important for the function of AML blasts as accessory cells during T cell activation, although the cytokine release would be expected to influence the accessory cell function at least when high levels are present. However, despite this wide variation in cytokine/cytokine antagonist release (Figure 1 ), AML blasts derived from different patients seem to have a similar immunoregulatory function with an inhibition of the Th1 associated (IL2, IFN␥ and IL13) cytokine responses. 61, 136 The alterations in IFN␥ and IL13 release are then secondary to the decreased IL2 secretion and can be counteracted by addition of exogenous IL2.
61
Release of immunosuppressive soluble mediators by AML blasts
Transforming growth factor ␤ Transforming growth factor (TGF) ␤ secretion by malignant cells can inhibit T cell responses (Table 3) , including the activation of tumor infiltrating lymphocytes derived from human tumors. 137, 138 For many patients the AML blasts show constitutive secretion of both TGF␤1 and TGF␤2, but there is a wide variation in TGF␤ levels between different patients. 139 Release of TGF␤ is important for AML blast-induced inhibition of LAK cell activity. 139 Thus, TGF␤ release seems to contribute to immune escape in AML. However, several other cells in the bone marrow microenvironment can also secrete TGF␤, including stromal cells, endothelial cells and megakaryocytes. 140 This local in vivo release of TGF␤ will probably induce the same effects on AML blasts as the in vitro exposure of the blasts to exogenous TGF␤:
(1) For most patients exogenous TGF␤ inhibits proliferation of native AML blasts both when cultured in medium alone (spontaneous proliferation 141, 142 ) and in the presence of exogenous thrombopoietin, 143 G-CSF, 144 GM-CSF, 141, 144 IL3, 141, 144 IL6, 144 stem cell factor (SCF 141, 145 ) and GM-CSF+IL3+SCF. 146 The inhibition is strongest for lineagespecific factors, and these results therefore suggest that the susceptibility to growth suppression by TGF␤ increases with the progression of clonal evolution. 141 (2) AML blast resistance to the TGF␤-induced growth inhibition has been observed in AML secondary to myelodysplastic syndromes, 147 and for a minority of de novo AML patients TGF␤ may even enhance blast proliferation
in the presence of exogenous GM-CSF, M-CSF, IL3 or SCF. 142, 144 (3) The antiproliferative effects of TGF␤ on native AML blasts is probably caused by a combination of decreased growth factor receptor expression, 145 but TGF␤ may in addition alter secretion of autocrine growth factors 144 and induce differentiation in the blasts. 148, 149 (4) TGF␤ can also induce apoptosis in AML cell lines possibly by decreasing endogenous expression of the growthpromoting factor Bcl-2.
150,151
TGF␤ released by AML blasts or by other cells in the bone marrow microenvironment may in addition suppress T lymphocyte responses. Thus, whether TGF␤ should be regarded as mainly an immunosuppressive. AML-inhibitory or AMLenhancing cytokine is determined by the relative strength of these three effects, and the dominating effect in each patient will thus depend both on the local cytokine network as well as individual differences between patients.
Soluble IL2 receptors
IL2 is important both as a growth factor for antigen-activated T cells and for the generation on non-HLA-restricted LAK cell activity (see Ref. 152) . IL2 therapy has therefore been tried in AML, and the overall results indicate that AML patients with limited disease may respond to IL2 therapy and achieve disease control lasting for several months. [153] [154] [155] [156] These results suggest that IL2-dependent antileukemic immune reactivity contributes to disease control, and IL2 binding soluble receptors may therefore contribute to immune escape in AML.
Analysis of membrane molecule and mRNA expression have demonstrated that AML blasts express both ␣-, ␤-and ␥-chains of the IL2 receptor, [157] [158] [159] but in vitro exposure of AML blasts to IL2 does not seem to have any major effect on blast proliferation. 160, 161 However, serum levels of soluble IL2 receptors are increased in AML patients, 162, 163 and experimental studies indicate that the increased levels are caused by receptor release from AML blasts. 163 This release of biologically active soluble IL2 receptors may thereby contribute to immune escape by neutralizing IL2 and thereby inhibiting IL2-dependent antileukemic immune reactivity. 8, 152 
IL10 as a possible immunosuppressive agent
In vitro studies indicate that high levels of IL10 may be important for induction of an immunosuppressed status in malignant diseases (see Ref. 8) . However, constitutive AML blast release of IL10 cannot be detected for most patients 177 and IL10 secretion thus does not seem to contribute to an immunosuppressed status in AML patients.
Soluble adhesion molecules
Several adhesion molecules exist both in membrane-bound and soluble forms which are biologically active and inhibit cell-cell adhesion (see Refs 102, [164] [165] [166] . LFA-3 and ICAM-1 are expressed on most AML blasts (see above). Both these molecules can mediate costimulatory signals and may thus be important during T cell recognition of AML blasts. Soluble(s) ICAM-1 can be released both from normal cells and from AML blasts. [165] [166] [167] [168] Increased sICAM-1 serum levels have been detected in patients with untreated AML, 163, 169, 170 and the serum levels show a further increase during infectious complications. [171] [172] The soluble forms of ICAM-1 are biologically active and can block the adhesion of AML blasts to other cells, 173 and the increased levels of sICAM-1 may thereby inhibit ICAM-1-mediated costimulatory signalling during T cell recognition of AML blasts. It is not known whether LFA-3 also can be released by AML blasts in biologically active soluble forms which inhibit T cell/AML blast interactions.
Concluding remarks
Several observations indicate that T lymphocytes can recognize AML blasts and thereby mediate antileukemic reactivity: (1) T cells are involved in the pathogenesis of antileukemic GVHD; (2) AML blasts often have chromosomal abnormalities which can encode leukemia-specific antigenic peptide sequences; (3) AML blasts can process protein antigens and present antigenic peptides in the context of self-HLA; (4) AML blasts express costimulatory molecules and secrete cytokines which enhance T cell responses. AML blasts derived from different patients usually express high levels of the antigenpresenting HLA molecules, but the blasts are heterogeneous with regard to the amino acid sequence of the leukemia-specific peptides, the constitutive secretion of immunomodulatory soluble mediators, and the expression of costimulatory and apoptosis-inducing membrane molecules. This heterogeneity probably has to be reduced to make the effects of immunotherapy more predictable in individual patients and to make this therapeutic approach suitable for routine therapy. Both vaccination of patients with normal dendritic cells pulsed with AML blast extracts and selective enhancement of T cell responses to common antigens like teleomere or MUC1 epitopes have been suggested as possible approaches to overcome the problem of antigenic heterogeneity. [174] [175] [176] The wide variation in the constitutive secretion of immunomodulatory soluble mediators by AML blasts seems more difficult to overcome. Although exogenous cytokines can modulate this constitutive secretion the wide variation is usually detected even in the presence of the exogenous cytokines. For example, the cytokines IL4, IL10 and IL13 can reduce the in vitro constitutive cytokine release from AML blasts by up to 50-70%, but there is still a 4-log variation in the constitutive secretion when AML blasts derived from different patients are compared. [130] [131] [132] However, this variation may become less important if the variation in AML blast expression of costimulatory molecules can be reduced, because soluble mediators usually have only a modulatory effect whereas the costimulatory molecules are directly involved in T cell activation. This hypothesis is supported by in vitro studies which demonstrate that AML blasts can be induced to express a dendritic cell phenotype with increased expression of costimulatory molecules, and these cells are more efficient as accessory cells during T lymphocyte activation. Thus, taken together the present evidence suggests that immunotherapy involving enhancement of antileukemic T cell reactivity may become useful in routine clinical treatment, but further studies are needed to evaluate different therapeutic approaches before immunotherapy can be introduced in randomized clinical trials. 
